Table 5 The characteristics in GM patients with and without recurrence
From: A case management model for patients with granulomatous mastitis: a prospective study
Variables | No recurrence | Recurrence | Test statistic | P |
|---|---|---|---|---|
BMI (kg/m2) | χ2 = 8.29 | 0.028 | ||
18.5–24.99 | 80 (59.26) | 5 (29.41) | ||
< 18.5 | 9 (6.67) | 0 | ||
25–29.99 | 39 (28.89) | 11 (64.71) | ||
≥ 30 | 7 (5.18) | 1 (5.88) | ||
Side | χ2 = 3.234 | 0.345 | ||
Right | 53 (39.2) | 6 (35.3) | ||
Left | 73 (54.1) | 8 (47.1) | ||
Bilateral | 9 (6.7) | 3 (17.6) | ||
Mass size at onset | χ2 = 1.031 | 0.797 | ||
< 1 cm | 5 (3.7) | 1 (5.9) | ||
1–2.9 cm | 31 (22.9) | 4 (23.5) | ||
3–5 cm | 65 (48.2) | 7 (41.2) | ||
> 5 cm | 34 (25.2) | 5 (29.4) | ||
Laboratory tests before treatment | ||||
C. kroppenstedtii | χ2 = 1.317 | 0.453 | ||
Positive | 35 (24.6) | 1 (10) | ||
Negative | 107 (75.4) | 9 (90) | ||
White blood cell (WBC) | ||||
mean, *109/L | 9.7 ± 3.4 | 10.1 ± 3.1 | F = 0.197 | 0.658 |
C-reactive protein (CRP) mean, mg/L | 12.3 ± 19.9 | 8.8 ± 6.9 | ||
F = 0.53 | 0.468 | |||
Prolactin (PRL) mean, ng/mL | 22.1 ± 19.8 | 27.2 ± 19.0 | F = 0.924 | 0.338 |
Types of GM | χ2 = 4.857 | 0.2 | ||
Mass type | 65 (48.2) | 9 (52.9) | ||
Abscess type | 59 (43.7) | 7 (41.2) | ||
Refractory type | 11 (8.1) | 1 (5.9) | ||
Treatments | χ2 = 7.429 | 0.02 | ||
Medical + Breast lesion excision by minimally invasive surgery | 17 (12.7) | 2 (11.8) | ||
Medical + Breast lesion excision by open surgery | 50 (37.0) | 12 (70.6) | ||
Medication | 67 (49.6) | 3 (17.6) | ||
Observation | 1 (0.7) | 0 | ||
Medication | χ2 = 7.175 | 0.018 | ||
Single steroids | 77 (57.0) | 7 (41.2) | ||
Single tubercle bacillus drug | 20 (14.8) | 0 | ||
Combined medication | 37 (27.5) | 10 (58.8) | ||
Without medication | 1 (0.7) | 0 | ||
Medication adherence | χ2 = 5.932 | 0.046 | ||
Low | 17 (12.7) | 6 (35.3) | ||
Median | 63 (47.0) | 8 (47.1) | ||
High | 54 (40.3) | 3 (17.6) | ||
Follow-up time, m | 24.55 | 24.41 | F = 0.015 | 0.901 |